

META HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration 198804700N)

COMPLETION OF SALE OF WHOLLY-OWNED SUBSIDIARIES

The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”) refers to the Company’s announcements on 21 November 2023 and 18 January 2024, and the Company’s circular to shareholders dated 7 December 2023 (the “**Circular**”), in relation to the sale (the “**Sale**”) of the entire issued and paid-up share capital of MCE Technologies (Suzhou) Co., Ltd. (“**MCE Suzhou**”), as well as the Company’s announcement dated 22 December 2023 in relation to the results of the extraordinary general meeting held on 22 December 2023 where the shareholders of the Company approved the Sale.

Unless otherwise defined or required by the context, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Circular.

The Board is pleased to announce that the Registration Procedures have been completed on 23 January 2024. Accordingly, MCE Suzhou and MCE Shanghai (a wholly-owned subsidiary of MCE Suzhou) have ceased to be subsidiaries of the Company and the Group on the same date.

BY ORDER OF THE BOARD

Lee Wei Hsiung
Company Secretary
25 January 2024

*This announcement has been prepared by Meta Health Limited (the “**Company**”) and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “**Sponsor**”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.